Abemaciclib
FANCL Gene Mutation
University of California, DavisSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the FANCL Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Niraparib University of California, Davis | Phase 2 | CCC |
Same molecule, other indications
Abemaciclib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →